AI/ML-Enabled Drug Discovery – Part 1

Paid

Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying novel drug targets, drug design, virtual screening, lead optimization, and ADME/toxicology assessments.

26-27 September 2023

Healthcare

Small Molecules for Cancer Targets – Part 1

Paid

Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules offer the promise of medicine in pill form and more affordability than do biologics, but they also

26-27 September 2023

Healthcare

Neurodegeneration Targets

Paid

Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets conference focuses on therapeutic candidates in clinical or earlier stage development that modulate molecules or cellular processes involved in neurodegenerative diseases, especially Alzheimer’s and Parkinson’s disease. Neurodegenerative diseases have a dearth of therapeutic opti

26-27 September 2023

Healthcare